Joint Clinical Trials Office

CT Open to Enrollment

Development of RPBM for Quantitative Assessment of Myofascial Pain

The purpose of this study is to develop MRI methods for more accurate evaluation of the jaw muscles for patients with masticatory myofascial pain syndrome (MMPS).

Study participation involves one 60-minute non-contrast MRI of the jaw. There is also an optional repeat MRI.

Participants will also complete a questionnaire (about 10-15 minutes) that has questions on topics including jaw pain and sleep quality any time prior to the MRI. 

Study participants will be compensated $100 for completing the study.

A Phase 3 randomized open-label study of belantamab mafodotin in combination with lenalidomide and dexamethasone versus daratumumab, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for auto-SCT

The goal of this clinical trial is to compare the safety and efficacy of belantamab mafodotin combinated with lenalidomide and dexamethasone to the combination of daratumumab, lenalidomide and dexamethasone in participants who have newly diagnosed multiple myeloma and are not eligible for autologous stem cell transplantation. The study also wants to determihne if the study drug is safer and works better than the current standard of care treatment.

Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108

This registry study is being done with the Thoracic Surgery Oncology Group (TSOG), which is a collaboration between Memorial Sloan Kettering (MSK) and the American Association for Thoracic Surgery (AATS) to support thoracic surgery clinical trials. We hope to learn more about how different doctors perform the pulmonary segmentectomy surgery and how this type of surgery affects people with lung cancer.

Participants are being asked to join because they will undergo surgery and may or may not have lung cancer.

A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis

The study is researching an experimental drug called dupilumab (called “study drug” in this form) for children with active eosinophilic esophagitis (EoE). EoE is an inflammatory disease of the esophagus which impacts feeding and nourishment.

Experimental means that dupilumab is not approved by the U.S. Food and Drug Administration (FDA).

A Phase 1b/2, Multicenter, Randomized, Open-Label Study to Evaluate The Efficacy And Safety Of GSK5764227 Alone And In Combination In Participants With Previously Treated Advanced Unresectable Or Metastatic Gastrointestinal Solid Tumors

This clinical trial is for adults who have been diagnosed with advanced or metastatic colorectal cancer (CRC) OR advanced or metastatic pancreatic cancer (PDAC).

A Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia

The purpose of this study is to evaluate the safety and effectiveness of BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia.
   
In this study BAL0891, tislelizumab and paclitaxel will be given intravenously (meaning through a needle in the vein directly into the blood). 
   
Total length of participation in this research will vary depending on disease status.

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician’s Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma

 This clinical trial is for men and women with returned (relapsed) and/or has not responded to previous treatments (refractory) Peripheral T cell Lymphoma, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.
   
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug soquelitinib versus standard of care treatments. Investigational means that soquelitinib has not been approved by the U.S. Food and Drug Administration (FDA).
   

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

This clinical trial is for men and women with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) to evaluate the safety and effectiveness of ELA026.
   
In this study, ELA026 will be given intravenously (meaning through a needle in the vein directly into the blood).
   
Participation is expected to last about 3 years. Participants will be admitted to the hospital at the start of the study during the administration of ELA026.

A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma

The purpose of this study is to test the good and bad effects of the drug called durvalumab in combination with the chemotherapy drugs gemcitabine and cisplatin. We are doing this study because we want to find out if this approach is better or worse than the usual approach for liver cancer.

The combination of gemcitabine, cisplatin, and durvalumab has been approved by the U.S. Food and Drug Administration (FDA) as front line therapy for advanced biliary tract cancers, including intrahepatic cholangiocarcinoma.

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

This trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs).